Previous 10 | Next 10 |
2023-03-09 11:08:04 ET Cellectis S.A. (CLLS) Q4 2022 Earnings Conference Call March 9, 2023 08:00 ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Mark Frattini - Chief ...
2023-03-08 16:53:49 ET Cellectis press release ( NASDAQ: CLLS ): Q4 GAAP EPS of -$0.02 beats by $0.58 . Revenue of $17.32M (+792.8% Y/Y) misses by $4.93M . For further details see: Cellectis GAAP EPS of -$0.02 beats by $0.58, revenue of $17.32M misses by ...
Entered into a € 40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from P...
2023-03-07 17:35:20 ET Major earnings expected after the bell on Wednesday include: MongoDB ( MDB ) Asana ( ASAN ) Vermilion Energy ( VET ) Assertio Holdings ( ASRT ) Orion Office REIT ( ONL ) For further details see: Notable earnings afte...
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based sy...
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth qu...
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announce...
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accor...
Cellectis S.A. ( NASDAQ: CLLS ) has priced its previously announced $22M underwritten global offering by way of a capital increase of 8.8M American Depositary Shares at $2.50/ADS. Each ADS represents the right to receive one ordinary share of Cellectis, nominal value €0.05 ...
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announce...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...